Shots:

• The termination is based on P-III EMERGE and ENGAGE study results assessing Aducanumab vs PBO in ~ 3-200 patients with mild cognitive impairment due to Alzheimer’s disease and dementia across the world
• The termination is due to its inability to meet 1EPs resulted in the loss of ~$18B to Biogen. Biogen also terminates P-II EVOLVE study of Aducanumab and the long-term extension of PRIME leads to falling in Biogen’s stock price up to 28%
• Aducanumab (BIIB037) is a mAb evaluated for the treatment of Alzheimer’s disease. On Oct-2017 Biogen & Eisai collaborated for the development & commercialization of aducanumab globally

Click here to read full press release/ article 

| Ref: Biogen | Image: Biogen